Following previous ticker characteristics, BioPharmX Corporation (NYSE:BPMX) also run on active notice, stock price knock down -17.93% after traded at $0.43 in most recent trading session. BioPharmX Corporation (BPMX) announced its financial results for the third quarter ended Oct. 31, 2016.
“It is an exciting time for BioPharmX. We recently raised a important amount of capital and presented expanded research that demonstrates the promise of BPX-01,” said Anja Krammer, president of BioPharmX Corporation. “During the quarter we reached several important milestones on our journey toward becoming a leading dermatology specialty pharmaceutical company.”
BPMX price to current year EPS stands at -722.10%. Whereas the traders who further want to see about this, may be interested to see Price to next year’s EPS that would be 20.60%. Moving toward ratio analysis, it has current ratio of 0.20 and quick ratio was calculated as 0.20.
Taking notice on volatility measures, price volatility of stock was 28.09% for a week and 23.35% for a month. The price volatility’s Average True Range for 14 days was 0.08. On these bases, analysts would recommend this stock as an “Active Revolving Stocks.” The firm attains analyst recommendation of 2.00 out of 1-5 scale with week’s performance of -7.50%. BPMX’s institutional ownership was registered as 22.40%, while insider ownership was 1.70%.
Exact Sciences Corporation (NASDAQ:EXAS) persists its position slightly strong in context of buying side, while shares price ascend 3.67% during latest trading session.
Narrow down focus to other ratios, the co has current ratio of 11.90 that indicates if EXAS lies in 1.3% to 3% then it is acceptable for both active and passive investors, but sometimes its varies industry to industry. Generally, it indicates good short-term financial strength. Street is more conscious on this after SunEdison, Inc. case. To make strengthen these views, the active industry firm has Quick Ratio of 11.70, which indicates firm has sufficient short-term assets to cover its immediate liabilities. In addition, the firm has debt to equity ratio of 0.02, sometimes its remain same with long term debt to equity ratio.